{"schema_version":"1","generated_at":"2026-11-05T08:38:21.998Z","data_as_of":"2026-11-04","url":"https://www.findmykol.com/kol/sean-adrean","json_url":"https://www.findmykol.com/kol/sean-adrean/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"sean-adrean","name":"Sean Adrean","credential":"MD","title":"Retina Specialist","specialty":"Retina Specialist","specialty_raw":"Retina Specialist","therapeutic_area":"Ophthalmology","therapeutic_areas":["Ophthalmology"],"institution":"Retina Consultants of Orange County","institution_url":"https://www.findmykol.com/institution/retina-consultants-of-orange-county","city":"Fullerton","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1073566568","orcid":"0000-0001-6004-0643","openalex":"A5047968636"},"summary":"Sean Adrean is Retina Specialist at Retina Consultants of Orange County. OpenAlex indexes 54 publications with 1,793 citations (h-index 13); ClinicalTrials.gov lists 1 registered study with this person as an investigator.","overview":{"text":"Sean Adrean, MD, is Retina Specialist at Retina Consultants of Orange County. The public record shows 54 publications with 1,793 citations (h-index 13), centered on Retinal Diseases and Treatments, Retinal and Macular Surgery, Ocular Diseases and Behçet’s Syndrome. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 28 companies.","bullets":["Top research focus: Retinal Diseases and Treatments","1 registered trials on ClinicalTrials.gov","Open Payments reporting from 28 companies"],"generated_at":"2026-11-04"},"focus":{"indications":[{"label":"Diabetic Complications","therapeutic_area":"Endocrinology/Metabolic","trials":1,"topics":0,"strength":3},{"label":"Diabetic Retinopathy / DME","therapeutic_area":"Ophthalmology","trials":1,"topics":0,"strength":3},{"label":"Edema","therapeutic_area":"Cardiology","trials":1,"topics":0,"strength":3},{"label":"Macular Edema","therapeutic_area":"Ophthalmology","trials":1,"topics":0,"strength":3},{"label":"Macular Degeneration (AMD)","therapeutic_area":"Ophthalmology","trials":0,"topics":0,"strength":1},{"label":"Glaucoma","therapeutic_area":"Ophthalmology","trials":0,"topics":0,"strength":1},{"label":"Lupus (SLE)","therapeutic_area":"Rheumatology/Immunology","trials":0,"topics":0,"strength":1}],"research_topics":["Retinal Diseases and Treatments","Retinal and Macular Surgery","Ocular Diseases and Behçet’s Syndrome","Ocular Infections and Treatments","Retinopathy of Prematurity Studies"],"drugs_studied":{"total":12,"shown":3,"withheld":9,"rows":[{"name":"Vabysmo","generic":"Faricimab","trials":0,"payments":61,"publications":3,"mentions":64},{"name":"Syfovre","generic":"Pegcetacoplan","trials":0,"payments":32,"publications":1,"mentions":33},{"name":"Ozurdex","generic":"Dexamethasone","trials":0,"payments":27,"publications":1,"mentions":28}]},"works_with":{"total":28,"shown":3,"withheld":25,"rows":[{"name":"Genentech USA, Inc.","trials":0,"payments":64,"mentions":64},{"name":"Apellis Pharmaceuticals, Inc.","trials":0,"payments":42,"mentions":42},{"name":"Regeneron Healthcare Solutions, Inc.","trials":0,"payments":31,"mentions":31}]}},"scholarship":{"works_count":54,"cited_by_count":1793,"h_index":13,"i10_index":14,"pubmed_count":13,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT06662994","title":"High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy","phase":"PHASE4","status":"RECRUITING","role":"Investigator","sponsor":"Retina Consultants of Orange County","source_url":"https://clinicaltrials.gov/study/NCT06662994","trial_url":"https://www.findmykol.com/trial/NCT06662994"}],"source":"trials"},"payments":{"company_count":28,"program_years":{"first":2021,"last":2025},"rows_total":61,"shown":3,"withheld":58,"rows":[{"payer":"Apellis Pharmaceuticals, Inc.","program_year":2025,"amount_usd":4468.1,"payment_count":17,"source_url":"https://openpaymentsdata.cms.gov/search?query=1073566568"},{"payer":"Ocular Therapeutix, Inc.","program_year":2025,"amount_usd":388.6,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1073566568"},{"payer":"Regeneron Healthcare Solutions, Inc.","program_year":2025,"amount_usd":277.16,"payment_count":8,"source_url":"https://openpaymentsdata.cms.gov/search?query=1073566568"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1073566568","source":"payments"},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"publications":{"total":13,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Evolving Congenital Hypertrophy of the Retinal Pigment Epithelium in a Pediatric Patient","year":2026,"journal":"Journal of VitreoRetinal Diseases","source_url":"https://doi.org/10.1177/24741264261430899","status":"verified"},{"title":"Impact of Baseline Best-Corrected Visual Acuity on Outcomes with Aflibercept 8 mg in Patients with Diabetic Macular Edema","year":2026,"journal":"Ophthalmology Retina","source_url":"https://doi.org/10.1016/j.oret.2026.03.018","status":"verified"},{"title":"ONE-YEAR RESULTS OF GEOGRAPHIC ATROPHY PATIENTS WITH PREEXISTING nAMD TREATED WITH BOTH ANTI-VEGF THERAPY AND PEGCETACOPLAN","year":2026,"journal":"Retina","source_url":"https://doi.org/10.1097/iae.0000000000004915","status":"verified"},{"title":"Neovascular age-related macular degeneration complicated by large submacular hemorrhage managed with faricimab monotherapy","year":2025,"journal":"International Journal of Retina and Vitreous","source_url":"https://doi.org/10.1186/s40942-025-00771-5","status":"verified"},{"title":"Sozinibercept: Is the Tide Turning for Better Visual Outcomes in Neovascular Age-related Macular Degeneration?","year":2025,"journal":"touchREVIEWS in Ophthalmology","source_url":"https://doi.org/10.17925/usor.2025.19.1.4","status":"verified"}],"most_cited":{"total":54,"shown":5,"withheld":49,"rows":[{"title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","year":2023,"cited_by_count":512,"type":"article","source_url":"https://doi.org/10.1016/s0140-6736(23)01520-9"},{"title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","year":2022,"cited_by_count":504,"type":"article","source_url":"https://doi.org/10.1016/s0140-6736(22)00018-6"},{"title":"Faricimab Treat-and-Extend for Diabetic Macular Edema","year":2023,"cited_by_count":176,"type":"article","source_url":"https://doi.org/10.1016/j.ophtha.2023.12.026"},{"title":"Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration","year":2023,"cited_by_count":111,"type":"article","source_url":"https://doi.org/10.1001/jamaophthalmol.2023.2421"},{"title":"Autologous Retinal Transplantation for Primary and Refractory Macular Holes and Macular Hole Retinal Detachments","year":2020,"cited_by_count":98,"type":"article","source_url":"https://doi.org/10.1016/j.ophtha.2020.10.007"}]},"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"linkedin","url":"https://www.linkedin.com/in/sean-adrean-1a988213","status":"verified"}]},"mentions":{"total":5,"shown":3,"rows":[{"url":"https://www.instagram.com/p/DdhjZuKkrf5/","platform":"instagram","status":"provisional"},{"url":"https://ophthalmology360.com/retina/photon-trial-assesses-aflibercept-8-mg-for-diabetic-macular-edema/","platform":"other","status":"provisional"},{"url":"https://www.asrs.org/find-a-specialist/profile/2456/Sean-David-Adrean","platform":"other","status":"provisional"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":3,"shown":3,"rows":[{"value":"MD, Loma Linda University","source_url":"https://retinaconsultants-socal.com/sean-d-adrean-m-d/","status":"verified","collected_at":"2026-11-04"},{"value":"Degree in Chemistry, University of California at San Diego (Magna Cum Laude)","source_url":"https://www.providence.org/doctors/retina-and-vitreous-diseases/ca/fullerton/sean-adrean-1073566568","status":"provisional","collected_at":"2026-11-04"},{"value":"Diplomate, The American Board of Ophthalmology","source_url":"https://retinaconsultants-socal.com/sean-d-adrean-m-d/","status":"verified","collected_at":"2026-11-04"}]},"roles":{"total":5,"shown":3,"rows":[{"value":"Fellow, American Academy of Ophthalmology","source_url":"https://retinaconsultants-socal.com/sean-d-adrean-m-d/","status":"verified","collected_at":"2026-11-04"},{"value":"FASRS, American Society of Retina Specialists","source_url":"https://www.asrs.org/find-a-specialist/profile/2456/Sean-David-Adrean","status":"verified","collected_at":"2026-11-04"},{"value":"Editor for multiple journals in ophthalmology","source_url":"https://retinaconsultants-socal.com/sean-d-adrean-m-d/","status":"verified","collected_at":"2026-11-04"}]},"awards":{"total":1,"shown":1,"rows":[{"value":"'The Best Cowhand' Award, Vit-Buckle Society for Surgical Video Excellence","source_url":"https://www.instagram.com/p/C95TRD4PgKo/","status":"provisional","collected_at":"2026-11-04"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"Board member, OCEP","source_url":"https://www.instagram.com/p/DdhjZuKkrf5/","status":"provisional","collected_at":"2026-11-04"}]},"media":{"total":3,"shown":3,"rows":[{"value":"HCPLive interview on baseline VA and aflibercept 8 mg outcomes in DME","source_url":"https://www.hcplive.com/view/sean-adrean-md-impact-baseline-va-aflibercept-8-mg-outcomes-dme","status":"provisional","collected_at":"2026-11-04"},{"value":"Ophthalmology360 article on PHOTON trial aflibercept 8 mg in DME","source_url":"https://ophthalmology360.com/retina/photon-trial-assesses-aflibercept-8-mg-for-diabetic-macular-edema/","status":"provisional","collected_at":"2026-11-04"},{"value":"The Doctor's Channel video on central retinal thickness and DME outcomes (PHOTON post hoc)","source_url":"https://www.thedoctorschannel.com/view/impact-of-central-retinal-thickness-on-outcomes-in-dme/","status":"provisional","collected_at":"2026-11-04"}]}},"similar":[{"name":"Robert Weinreb","slug":"robert-weinreb","institution":"University of California San Diego","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/robert-weinreb","json_url":"https://www.findmykol.com/kol/robert-weinreb/profile.json"},{"name":"Emily Chew","slug":"emily-chew","institution":"National Eye Institute","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/emily-chew","json_url":"https://www.findmykol.com/kol/emily-chew/profile.json"},{"name":"Harry Quigley","slug":"harry-quigley","institution":"Johns Hopkins University School of Medicine","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/harry-quigley","json_url":"https://www.findmykol.com/kol/harry-quigley/profile.json"},{"name":"Joel Schuman","slug":"joel-schuman","institution":"Wills Eye Hospital","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/joel-schuman","json_url":"https://www.findmykol.com/kol/joel-schuman/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":58,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-11-04"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-04"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-11-04"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}